Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens
Publication Type:
Journal Article
Authors:
Eron, J.J.;
Lalezari, J.;
Slim, J.;
Gathe, J.;
P J Ruane;
Wang, C.;
Elion, R.;
Blick, G.;
Khatri, A.;
Hu, Y.B.;
Gibbons, K.;
Fredrick, L.;
Co, M.;
D'Amico, R.;
Da Silva-Tillmann, B.;
Trinh, R.;
M S SulkowskiSource:
J Int AIDS Soc, Volume 17, Issue 4 Suppl 3, p.19500 (2014)
Keywords:
abnormalities,
Affect,
Antiretroviral,
Antiretroviral Therapy,
Arm,
atazanavir,
Baltimore,
Bilirubin,
Chicago,
Clinical Medicine,
co-infected,
co-infection,
coinfection,
Disease,
Genotype,
HCV,
Health,
hepatitis,
Hiv,
Hiv-1,
Hyperbilirubinemia,
Infectious Disease Medicine,
Jaundice,
Laboratories,
Los Angeles,
Medicine,
methods,
North Carolina,
Patients,
pharmacokinetic,
pharmacokinetics,
Plasma,
raltegravir,
Research,
Ribavirin,
ritonavir,
Rna,
Safety,
San Francisco,
Statistics,
SVR,
therapy,
treatment,
treatment-naive,
Universities,
Washington
Notes:
PMC4224905
